Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial
Extended analysis from PARSIFAL confirmed no difference between fulvestrant and letrozole when combined with palbociclib for patients with endocrine-sensitive, HR-positive/HER2-negative ABC. Efficacy results were consistent with those reported in the pivotal first-line trials involving CDK4/6i. Progression within the first year on CDK4/6i may indicate a poorer prognosis.
Authors
- Erika Shimizu
- Serena Di Cosimo (ORCID: https://orcid.org/0000-0002-4666-8052)
- A Llombart-Cussac
- Eduardo Martínez-De Dueñas
- J. Ivorra Cortés (ORCID: https://orcid.org/0000-0001-6554-7451)
- F. Dalenc
- J.G. Gavila
- Meritxell Bellet (ORCID: https://orcid.org/0000-0001-8859-8307)
- M Sampayo-Cordero
- Duncan Wheatley (ORCID: https://orcid.org/0000-0002-1919-5114)
- Miguel Gil‐Gil (ORCID: https://orcid.org/0000-0003-1380-2718)
- Paul Henri Cottu (ORCID: https://orcid.org/0000-0001-6434-3932)
- Manuel Ruíz‐Borrego (ORCID: https://orcid.org/0000-0002-1181-5622)
- Ángela Antón
- Peter Schmid (ORCID: https://orcid.org/0000-0001-9817-5228)
- Kepa Amillano (ORCID: https://orcid.org/0000-0002-4961-9328)
- José Manuel Pérez-García (ORCID: https://orcid.org/0000-0003-4238-2046)
- Pilar Zamora (ORCID: https://orcid.org/0000-0003-2631-9653)
- M Fernandez
Institutions
- Barts Health NHS Trust (GB)
- Universidad de Zaragoza (ES)
- Royal Cornwall Hospital Trust (GB)
- Hospital Universitario La Paz (ES)
- Universidad Cardenal Herrera CEU (ES)
- MedSIR (Spain) (ES)
- Fundación Instituto Valenciano de Oncología (ES)
- Institut Català d'Oncologia (ES)
- Hospital Universitario Miguel Servet (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Institut Claudius Regaud (FR)
- Fundación Hospital Provincial de Castellón (ES)
- Hospital Universitari Sant Joan de Reus (ES)
- Hospital Universitario Virgen del Rocío (ES)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Vall d'Hebron Institute of Oncology (ES)
- Institut Curie (FR)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105309
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Pfizer
- AstraZeneca